CMV Reactivation is Associated with a Lower Incidence of Relapse After Allo-SCT for CML

Overview

Journal Bone Marrow Transplant

Specialty General Surgery

Date 2013 Apr 9

PMID 23562969

Citations 52

Authors

S Ito

P Pophali

Wu CO

E K Koklanaris

J Superata

G A Fahle

R Childs

M Battiwalla

A J Barrett

Affiliations

Soon will be listed here.

Abstract

Preemptive therapy at CMV reactivation has diminished post-transplant CMV mortality. Furthermore, recent studies suggest a favorable 'virus-versus-leukemia' effect from reactivating CMV, reducing relapse of AML after SCT. We studied the relationship of CMV reactivation with leukemic relapse in 110 patients with CML receiving HLA-identical sibling SCT between 1993 and 2008. Of these, 79 (72%) were in chronic phase, 5 in second chronic phase, 17 in accelerated phase and 9 in blast phase. A total of 97 patients (88%) received a myeloablative conditioning regimen, 97 received 4-log ex vivo T cell-depleted grafts and 13 received T-replete grafts. CMV reactivation before day 100 was observed in 72 patients (65.5%). At a median follow-up of 6.2 years, CMV reactivation < day 100 as a time-dependent covariate was an independent factor associated with decreased relapse. We conclude that CMV reactivation may contribute to a beneficial GVL effect in CML transplant recipients.

Citing Articles

Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12.

Jiang H, Nace R, Ferguson C, Zhang L, Peng K, Russell S Cell Rep Med. 2024; 6(1):101874.

PMID: 39694038 PMC: 11866437. DOI: 10.1016/j.xcrm.2024.101874.

NK- and T-cell repertoire is established early after allogeneic HSCT and is imprinted by CMV reactivation.

Schafer A, Calderin Sollet Z, Herve M, Buhler S, Ferrari-Lacraz S, Norman P Blood Adv. 2024; 8(21):5612-5624.

PMID: 39047210 PMC: 11550366. DOI: 10.1182/bloodadvances.2024013117.

Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia.

Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A Haematologica. 2024; 110(1):103-116.

PMID: 38934082 PMC: 11694110. DOI: 10.3324/haematol.2023.284716.

The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping.

Wu X, Ma X, Song T, Liu J, Sun Y, Wu D Ann Hematol. 2024; 103(3):917-933.

PMID: 38227006 PMC: 10866798. DOI: 10.1007/s00277-023-05509-7.

Natural killer cells- from innate cells to the discovery of adaptability.

Basilio-Queiros D, Mischak-Weissinger E Front Immunol. 2023; 14:1172437.

PMID: 37275911 PMC: 10232812. DOI: 10.3389/fimmu.2023.1172437.

References

Savani B, Rezvani K, Mielke S, Montero A, Kurlander R, Carter C . Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2005; 107(4):1688-95. PMC: 1895415. DOI: 10.1182/blood-2005-05-1897. View

Fletcher J, Prentice H, Grundy J . Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class.... J Immunol. 1998; 161(5):2365-74. View

Parkman R, Cohen G, Carter S, Weinberg K, Masinsin B, Guinan E . Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2006; 12(9):919-27. DOI: 10.1016/j.bbmt.2006.05.008. View

Boeckh M, Gooley T, Myerson D, Cunningham T, Schoch G, Bowden R . Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996; 88(10):4063-71. View

Thomson K, Mackinnon S, Peggs K . CMV-specific cellular therapy for acute myeloid leukemia?. Blood. 2012; 119(4):1088-90. DOI: 10.1182/blood-2011-10-383943. View

DAgostino R, Lee M, Belanger A, Cupples L, Anderson K, Kannel W . Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990; 9(12):1501-15. DOI: 10.1002/sim.4780091214. View

Behrendt C, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman S . Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant. 2009; 15(1):54-60. PMC: 2803021. DOI: 10.1016/j.bbmt.2008.10.023. View

Khoury H, Kukreja M, Goldman J, Wang T, Halter J, Arora M . Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2011; 47(6):810-6. PMC: 3896981. DOI: 10.1038/bmt.2011.194. View

Solomon S, Nakamura R, Read E, Leitman S, Carter C, Childs R . Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003; 31(9):783-8. DOI: 10.1038/sj.bmt.1703928. View

10.

Barrett A . CMV: when bad viruses turn good. Blood. 2011; 118(5):1193-4. DOI: 10.1182/blood-2011-06-354340. View

11.

Einsele H, Ehninger G, Hebart H, Wittkowski K, Schuler U, Jahn G . Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995; 86(7):2815-20. View

12.

Savani B, Montero A, Kurlander R, Childs R, Hensel N, Barrett A . Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant. 2005; 36(11):1009-15. DOI: 10.1038/sj.bmt.1705167. View

13.

Winston D, Gale R . Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplant. 1991; 8(1):7-11. View

14.

Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F . Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood. 2011; 119(2):399-410. DOI: 10.1182/blood-2011-08-372003. View

15.

Cortez K, Fischer S, Fahle G, Calhoun L, Childs R, Barrett A . Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients. J Infect Dis. 2003; 188(7):967-72. DOI: 10.1086/378413. View

16.

Hermouet S, Sutton C, Rose T, Greenblatt R, Corre I, Garand R . Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma. Leukemia. 2003; 17(1):185-95. DOI: 10.1038/sj.leu.2402748. View

17.

Elmaagacli A, Steckel N, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M . Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011; 118(5):1402-12. DOI: 10.1182/blood-2010-08-304121. View

18.

Ljungman P, Griffiths P, Paya C . Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002; 34(8):1094-7. DOI: 10.1086/339329. View

19.

Battiwalla M, Wu Y, Bajwa R, Radovic M, Almyroudis N, Segal B . Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant. 2007; 13(7):765-70. DOI: 10.1016/j.bbmt.2007.03.009. View

20.

Foley B, Cooley S, Verneris M, Pitt M, Curtsinger J, Luo X . Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2011; 119(11):2665-74. PMC: 3311280. DOI: 10.1182/blood-2011-10-386995. View